Cytori Therapeutics Inc. (USA) 

(Public, NASDAQ:CYTX)   Watch this stock   
Find more results for cytx
Nov 9, 2009
Q3 2009 Earnings Conference Call
Nov 9, 2009
Q3 2009 Earnings Release
Oct 27, 2009
BIOCOM Investor Conference
Sep 10, 2009
Rodman & Renshaw Annual Global Investment Conference
More events from AOL Finance »    

Key stats and ratios

Q3 (Sep '09) 2008
Net profit margin -489.00% -438.29%
Operating margin -461.47% -434.28%
EBITD margin - -411.91%
Return on average assets -107.66% -127.50%
Return on average equity - -
Employees 88 -

Address

3020 Callan Road
San Diego, CA 92121
United States - Map
+1-858-4580900 (Phone)
+1-858-4580994 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Options - Morningstar
Research Reports - Yahoo Finance
Annual Report (PDF) - AnnualReports.com

Cytori Therapeutics Inc. (USA) discussed on blogs

Cytori Therapeutics Inc. (USA) discussions

  View all discussions »

Description

Cytori Therapeutics, Inc. develops, manufactures, and sells medical technologies to enable the practice of regenerative medicine. The Company’s commercial activities are focused on cosmetic and reconstructive surgery in Europe and Asia-Pacific, and stem and regenerative cell banking (cell preservation) in worldwide. Its product pipeline includes the development of new treatments for cardiovascular disease, spinal disc degeneration, gastrointestinal disorders, liver and renal disease and pelvic health conditions. The Company’s Celution System family of products processes patients’ cells at the bedside in real time. During the year ended December 31, 2008, the Celution 800/CRS System was introduced into the European cosmetic and reconstructive surgery market through a network of medical distributors. The Celution 900/MB is marketed in Japan through its commercialization partner, Green Hospital Supply, Inc.

Officers and directors

Ronald D. Henriksen
Chairman of the Board
Age: 70
Bio & Compensation - Reuters
Christopher J. Calhoun
Chief Executive Officer, Director
Age: 43
Bio & Compensation - Reuters
Marc H. Hedrick M.D.
President, Director
Age: 46
Bio & Compensation - Reuters
Mark E. Saad
Chief Financial Officer
Age: 39
Bio & Compensation - Reuters
Seijiro N. Shirahama
President - Asia Pacific
Age: 55
Bio & Compensation - Reuters
Bruce A. Reuter
Senior Vice President - International Sales, Marketing & Distribution
Age: 60
Bio & Compensation - Reuters
Douglas Arm Ph.D.
Senior Vice President - Operations
Age: 40
Bio & Compensation - Reuters
Alexander M. Milstein M.D.
Vice President - Clinical Development
Age: 49
Bio & Compensation - Reuters
Kenneth K. Kleinhenz
Vice President - Quality & Regulatory Affairs
Age: 45
Bio & Compensation - Reuters
David M. Rickey
Director
Age: 53
Bio & Compensation - Reuters